Jci_page_head_homepage_01 Jci_page_head_homepage_02
Miho Nozaki, Eiji Sakurai, Brian J. Raisler, Judit Z. Baffi, Jassir Witta, Yuichiro Ogura, Rolf A. Brekken, E. Helene Sage, Balamurali K. Ambati, Jayakrishna Ambati
Published in Volume 116, Issue 2
J Clin Invest. 2006; 116(2):422–429 doi:10.1172/JCI26316
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 2

VEGF-A reduced CNV via VEGFR-1. (A) Anti–VEGFR-1 Ab (40 pmol), but not anti–VEGFR-2 Ab (1.7 pmol), abrogated inhibition of CNV by CoCl2, VEGF-A, and PlGF-1. *P < 0.01 compared with drug alone. Antibody against VEGFR-2 but not VEGFR-1 modestly reduced CNV compared with goat IgG (40 pmol). #P < 0.05 compared with goat IgG. n = 10–12 per data point. (B) VEGF-A and CoCl2 reduced CNV in wild-type mice but increased it in Vegfr1 tk–/– mice compared with PBS-injected fellow eyes. #P < 0.05 compared with PBS. n = 10 per data point. CoCl2, 0.77 nmol; VEGF-A, 0.1 pmol; VEGF-E, 0.11 pmol.